(Nasdaq: BSEM) Raises Its 2026 Revenue Floor For The Second Time This Year

On November 12th, BioStem Technologies, Inc. (Nasdaq: BSEM)

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: BSEM) Raises Its 2026 Revenue Floor For The Second Time This Year *Click Here To Get Our Alerts Faster Via SMS* November 12th Dear Reader, On November 12th, BioStem Technologies, Inc. (Nasdaq: BSEM) put out third quarter numbers and did something it also did in August. It raised the floor on guidance again. The 2026 revenue range moved to $28Mn to $29Mn from $26Mn to $29Mn. That is the second time this year the low end has gone up. Quarterly net revenue landed at $7.6Mn against $7.9Mn in Q2. Hospital business kept climbing, rising to $6.8Mn from $6.7Mn, while the physician office line slipped to $0.8Mn. Customers are buying deeper into the catalog. Accounts ordering two or more product lines rose 14% from Q2. Accounts ordering three or more rose more than 40%. The loss line went the other way. GAAP net loss of $(11.4)Mn, or $(0.64) a share. Adjusted EBITDA of negative $6.4Mn against a positive $2.7Mn a year earlier. Operating expenses of $14.1Mn on $4.3Mn of gross margin dollars. Cash of $1.0Mn at September 30th, down from $7.0Mn. That gap is the whole debate. BSEM is carrying the cost structure of a company generating far more than $7.6Mn a quarter, because it bought one. Management says it is finalizing a plan to cut annualized cash operating expenses by roughly $10Mn to $12Mn, with the full benefit starting in Q1 2027. Insiders are already in. On October 8th, the CEO and COO paid roughly $1Mn in cash to exercise options on 500K combined shares at $2.00 each. Company Breakdown: BioStem Technologies, Inc. (Nasdaq: BSEM) Here is the business in one breath BioStem processes donated perinatal tissue, the placental membranes recovered after scheduled deliveries, into allografts used to close wounds and support surgical repair. BioRetain®, CryoTek® and SteriTek® are the processing methods. Neox®, Clarix®, VENDAJE® and American Amnion™ are the labels. Pompano Beach, Florida is the base, accredited by the American Association of Tissue Banks and run to current Good Tissue and Good Manufacturing Practices standards. The company BSEM is today was assembled on January 21st, when it acquired BioTissue Holdings' surgical and wound care business for roughly $15Mn in cash, up to $10Mn contingent on a 510(k) clearance and up to $15Mn in commercial royalty milestones. That transaction handed over the Neox and Clarix franchises, roughly $29Mn of 2025 sales, a national field sales organization and the group purchasing contracts that reach hospital systems. In September, BSEM added VENDAJE to its Vizient and Premier contracts, two of the largest group purchasing organizations in the country. Additionally, their patent wall keeps growing. On October 1st, BSEM announced one newly issued U.S. patent and three notices of allowance covering placental and umbilical cord tissue technologies across wound care, surgical and joint applications. More Sources: BSEM Website. BSEM Presentation. On The Record: What Management Actually Said Read the Q3 release next to the September 11th H.C. Wainwright conference, and the sequencing becomes obvious. Company CEO Jason Matuszewski spent his time on infrastructure. Sales logistics, invoicing and collections moved over from BioTissue at the start of August, and BSEM's own CRM platform is now live and tied into its ERP system. Not a growth boast. A plumbing report. Chief Commercial Officer Barry Hassett gave the field math in September: BSEM inherited 15 W-2 reps from BioTissue, has grown to 30, and is targeting more than 40 W-2 representatives and more than 30 independent agents by year-end. A fully ramped rep, management said, should reach a $750K to $1Mn annual run rate within 15 to 18 months. He put the addressable surgical and wound care set near $26Bn, against inherited group purchasing agreements that already reach more than 70% of U.S. hospital beds. Then comes the number that actually decides this file. Gross margin slipped to 56% in Q3 from 61% because pricing under the BioTissue supply agreement stepped up once the initial discount expired. Bring manufacturing in house, management has said, and the blended figure could move 15 to 20 points. The Neox and Clarix technology transfer to Pompano Beach is described as on track, with in-house production expected in the first half of 2027. Matuszewski said BSEM is "on track to become a fully vertically integrated company with those product lines." 7 Potential Catalysts Pinning (Nasdaq: BSEM) To Our Radar #1. A Float Of Under 14Mn Shares Means The Potential For Volatility Could Be Significant. With a float near 13.63Mn shares, BSEM registers as a low float idea, which means the potential for heightened volatility may be significant. #2. Guidance Went Up Again Inside A Loss-Making Quarter. Companies rarely lift the low end of a revenue range twice in one year while reporting a widening loss, and BSEM did exactly that on November 12th. #3. There Is Analyst Coverage With A $7 Target. H.C. Wainwright currently maintains a $7.00 target, representing a meaningful potential upside for BSEM from current levels. #4. An FDA-Cleared Product Sits One Payment Away From Launch. Catalyze received FDA 510(k) clearance on June 5th, and BSEM says it is working with BioTissue to restructure the still-unpaid $10.0Mn Clearance Payment tied to it to lower near-term cash obligations. #5. Hospital Access Keeps Widening Beyond Current Revenue Reach. VENDAJE now sits on Vizient and Premier contracts alongside inherited group purchasing agreements that touch more than 70% of U.S. hospital beds, far wider than the $6.7Mn of Q2 hospital revenue BSEM booked against it. #6. A Second Clinical Readout Remains On The 2026 Calendar. In August, BSEM said top-line venous leg ulcer data is expected in the second half of 2026, which would give it a second dataset behind the same processing platform. #7. Management Exercised Options Worth Roughly $1Mn. After the quarter closed, BSEM's CEO and COO exercised options for about $1Mn in cash, per the company. The Bottom Line The blueprint at BioStem Technologies, Inc. (Nasdaq: BSEM) is coming into focus. Acquire the hospital channel. Build the sales force. Cut the run rate. Then take manufacturing back and let margin do the work. The early evidence is stacking up. Two raised guidance floors in one year. Hospital revenue still climbing. Customers ordering across more product lines. A Nasdaq listing. And management putting roughly $1Mn of its own cash on the table. We're initiating coverage on BioStem Technologies, Inc. (Nasdaq: BSEM). Be on the lookout for updates heading your way soon. Talk again shortly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 11/12/2026 and ending on 11/13/2026 to publicly disseminate information about (BSEM:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC ten thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid forty five thousand USD ("Funds"). These Funds were part of the ten thousand USD funds that TD Media LLC received from a third party named Sideways Frequency LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (BSEM:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/bsem-uq4vg/#details

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice